Engflag

Turex

Quick links to important sections

Turex

Turex_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Turex

The foundational understanding of Turex is derived from its active chemical composition and its definitive pharmacological classification as a prescription-only anti-infective agent.

Property Description
Active ingredient Roxithromycin (INN)
Form Oral Tablet (Film-coated)
Pharmacological class Macrolide Antibiotic
General purpose Anti-infective agent (treats susceptible bacterial infection)
Origin Semi-synthetic derivative

Defining Turex: A Macrolide Antibiotic

Turex is a medicinal product classified as a prescription antibiotic that contains the substance Roxithromycin as its single active ingredient. This medication belongs to the macrolide group of antibiotics, a classification confirmed by its international ATC code J01FA06. Roxithromycin is recognized for its use against a broad spectrum of susceptible bacterial organisms. The product is formulated for the oral route and is supplied as a film-coated tablet intended for systemic absorption.

Composition and Semi-Synthetic Origin

The therapeutic effectiveness of Turex is due to Roxithromycin, which is a semi-synthetic derivative of the naturally occurring macrolide, Erythromycin. This derivation is a differentiating feature, as it involves a targeted chemical modification designed to enhance the drug's stability. This structural change allows Roxithromycin to exhibit significantly improved stability against the stomach's acidic environment, leading to better overall bioavailability compared to its natural precursor. The improved absorption profile means the body can more effectively utilize the active medicine.

General Purpose and Mechanism of Effect

The primary general purpose of Turex is to serve as an effective anti-infective agent for managing susceptible bacterial infections. Roxithromycin achieves this by interfering directly with the bacteria's ability to grow and multiply. It works at a high level by binding to the 50S ribosomal subunit, which prevents the bacteria from synthesizing the proteins they need to survive. This targeted molecular interference leads to a bacteriostatic effect, meaning it substantially limits the proliferation of the bacteria, aiding the body’s immune system in resolving the disease state.

Regulatory References

  1. NIH MedlinePlus: Roxithromycin

What side effects are possible with Turex?

The safety profile of Turex (Roxithromycin) is officially documented by regulatory agencies and classified by frequency and affected physiological system. Adverse reactions are grouped using System-Organ Classes (SOCs), with the Gastrointestinal Disorders system being the most commonly cited source of side effects.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Common (ge 1/100 to < 1/10) Nausea, Vomiting, Diarrhea, Abdominal pain (epigastric pain), Anorexia, Rash.
Uncommon (ge 1/1,000 to < 1/100) Headache, Dizziness, Vertigo.
Rare to Frequency Not Known Alteration in the senses of smell and taste, Urticaria, Severe skin reactions, Cardiac arrhythmias.

Serious Adverse Reactions and Constraints

The official labeling notes the possibility of rare but clinically significant adverse reactions. These include Anaphylactic Shock and severe generalized hypersensitivity reactions. Serious events affecting organ systems include Fulminant Hepatitis (rarely fatal) within Hepatobiliary Disorders and Ventricular Arrhythmias, such as Torsades de Pointes, associated with Cardiac Disorders and QT interval prolongation. Pseudomembranous Colitis, an intestinal condition linked to Clostridium difficile infection, is documented as a possible severe gastrointestinal event that may occur up to several weeks after treatment cessation.

Population-Specific Constraints: Use is generally contraindicated in patients with severe hepatic impairment. Caution is noted for older adults due to a potential increased risk of cardiac arrhythmia. The medication may also exacerbate or aggravate Myasthenia Gravis, a condition concerning muscle weakness.

Overdose and Emergency Response

A suspected overdose of Turex (Roxithromycin) requires urgent medical attention due to the potential for severe, life-threatening effects. Official regulatory labeling mandates immediately contacting a doctor or Poisons Information Centre, or proceeding directly to the Emergency Department at the nearest hospital. This critical action is required even if there are no signs of discomfort or apparent poisoning following the over-ingestion of a large dose.

The documented clinical profile of Turex overdose centers on two major systems. Acute overexposure may present with gastrointestinal disturbances, including nausea, vomiting, and diarrhoea. More critically, the macrolide classification carries a documented risk of cardiac toxicity. This risk is primarily associated with Prolongation of the QT interval, which can lead to severe Ventricular arrhythmias such as Torsades de pointes. This level of severity requires immediate response.

Management, as described in regulatory documents, is symptomatic and supportive, as there is no specific antidote known. Procedures to manage an overdose often include gastric lavage to remove unabsorbed substance and require subsequent continuous ECG monitoring for the cardiac risk. Patients with severely impaired hepatic function are noted as a population potentially at increased risk.

Therapeutic Uses of Turex

What Turex Treats: Main Uses and Benefits

Turex (Roxithromycin) is a prescription macrolide antibiotic applied across several therapeutic domains to address bacterial infections in conditions presenting with systemic or localized discomfort. It is an anti-infective agent used in recognized therapeutic applications to manage the overall symptom load and help maintain a sense of stability when symptoms are more noticeable.

The medication is commonly used to manage acute episodes of bacterial respiratory tract infections (including bronchitis and pharyngitis), skin and soft tissue infections (like cellulitis), and specific urogenital infections (such as those caused by Chlamydia). It is applied in clinical settings marked by acute or unstable symptom patterns, helping to relieve symptoms related to inflammatory or irritative states and physical discomfort.

Quick Fact: Support for Symptoms Related to Acute Discomfort

It is commonly used to help manage symptom clusters that may become intense or disruptive, such as severe sore throat, persistent coughing, localized pain, and fever. It offers symptomatic assistance that may help patients cope more steadily with these difficult episodes and supports general well-being during symptomatic phases.

Regulatory References

  1. New Zealand's Medsafe regulatory body

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Turex — Official Regulatory Information

The eligibility profile for Turex (Roxithromycin) is strictly defined by official regulatory labeling, outlining specific populations and co-existing conditions that determine use.

Eligibility Status Description of Regulatory Rule
Populations Allowed Adults and older adults are eligible for standard use. Children with a body weight of more than 40 kg are eligible for the adult dose. Patients with renal insufficiency typically require no dosage adjustment.
Populations Contraindicated Absolute prohibition for patients with known hypersensitivity to any macrolide antibiotic or to Roxithromycin. Contraindicated in patients with severely impaired hepatic function. Must not be used concurrently with vasoconstrictive ergot alkaloids or specific QT-prolonging agents (e.g., cisapride, astemizole).

Age and Condition Restrictions

Category Regulatory Rule/Restriction
Age-Related Rule The tablet formulation is not recommended for children with a body weight of less than 40 kg.
Hepatic Function Not recommended in cases of severe hepatic insufficiency. Use with caution in subjects with mild to moderate hepatic impairment.
Reproductive Status Use during pregnancy and lactation is generally not recommended and is restricted to cases where it is clearly indicated by the prescribing physician.

Connection to the overall eligibility profile: Official regulatory documents classify these restrictions as either Contraindicated (absolute ban) or Not Recommended (conditional use), defining the mandatory limits for prescribing. These rules are grounded in patient history, physiological function (like hepatic status), and concomitant drug therapy, forming the non-negotiable basis of who is eligible for treatment with Roxithromycin.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific, clinically relevant interactions for Roxithromycin (Turex). Co-administration with certain substances can result in altered plasma concentrations of either drug or an increased risk of adverse effects.

Contraindicated and High-Risk Combinations

Official labeling formally contraindicates the combination of Roxithromycin with Vasoconstrictive Ergot Alkaloids (e.g., Ergotamine, Dihydroergotamine) due to the serious risk of ergotism. The use of Roxithromycin is also advised against with medicines such as Pimozide and Cisapride, as the combination elevates the risk of QT interval prolongation and severe cardiac arrhythmias.

Exposure Modification and Pharmacodynamic Effects

Roxithromycin may cause an increase in the plasma concentration of several co-administered medicines, including the cardiac glycoside Digoxin (linked to P-glycoprotein inhibition), Theophylline, Ciclosporin, and Midazolam. The concurrent use with the anticoagulant Warfarin can increase the International Normalised Ratio (INR), reflecting an enhanced anticoagulant effect. Additionally, co-administration with Class IA and Class III Antiarrhythmics carries an increased risk of cardiovascular adverse effects.

Administration Requirements

Administration with food is officially documented to result in decreased absorption of Roxithromycin. Consequently, the medicine must be taken on an empty stomach (e.g., at least 15 minutes before a meal). Official notes also indicate that the drug's clearance is altered in cases of hepatic impairment, which can enhance the clinical significance of these documented interactions.

Mechanism of Action

Turex contains Roxithromycin, a macrolide that exerts its effect through the selective inhibition of bacterial protein synthesis. The molecule functions as a ribosomal inhibitor by targeting the 50S ribosomal subunit within susceptible bacteria. Roxithromycin achieves this by reversibly binding to a specific site on the 23S ribosomal RNA near the peptidyl transferase center, effectively blocking the ribosome's exit tunnel.

This binding structurally obstructs the translocation step of the ribosome, thereby preventing peptide chain elongation and the synthesis of necessary bacterial proteins, enzymes, and virulence factors. This primary action induces a state of bacteriostasis , arresting the growth and proliferation of the microbial population.

The resultant halt in replication reduces the active bacterial load, supporting the host’s immune system response to the static population. The mechanism is constrained by bacterial resistance, primarily through efflux pumps that expel the drug or mutations in the 23S rRNA that physically block its binding to the 50S target.

Dosage and Administration Information

How to Use Turex: Official Administration Guidelines

Turex is an oral macrolide antibiotic containing Roxithromycin that is administered according to standardized protocols governing its dose, frequency, and timing. The medication is supplied as film-coated tablets in strengths such as 150 mg and 300 mg. All usage patterns follow clinical prescribing information and are not subject to patient interpretation.

Standard Dosage and Frequency

The established total daily dose for adults is 300 mg. This may be administered via two recognized high-level schedules based on clinical practice:

  • Twice Daily Regimen: 150 mg taken every twelve hours.
  • Once Daily Regimen: 300 mg taken as a single dose.

For most conditions, the course of treatment is defined as a finite duration, typically spanning five to ten days. For certain infections, such as those caused by Streptococcus, clinical guidelines specify a minimum course of ten days.

Contextual Administration and Adjustments

To optimize its high-level use pattern, Turex tablets must be taken on an empty stomach. Standardized instructions define this specifically as taking the tablet at least 15 minutes before food or a minimum of three hours following a meal. The tablets must be swallowed whole with a drink and not crushed or split.

Clinical prescribing information outlines specific requirements for certain patient populations, notably in cases of severely reduced liver function. For patients with severe hepatic insufficiency, the standard total daily dose must be reduced by half, typically to 150 mg once daily. No equivalent dose adjustment is generally required for older adults or patients with renal impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Turex

Evidence for use in Respiratory Tract Infections (RTIs)

Research exploring the use of Roxithromycin for acute Respiratory Tract Infections (RTIs), such as bronchitis and pharyngitis, has largely been conducted through a high number of Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in symptoms related to physical discomfort. Researchers in these trials frequently compared Roxithromycin against other treatments and measured outcomes related to systemic or functional imbalance.

These studies monitored outcomes related to both clinical improvement (how quickly a patient's symptoms evolved during the study period, like change in fever or cough) and bacteriological eradication (whether the infection-causing bacteria was successfully cleared from the body). What remains uncertain is the long-term status of patients after treatment is complete. Research indicates that studies have described a pattern where observed clinical improvement occurred even when the microbiological tests still appeared to detect the presence of the pathogen. This discrepancy highlights a known challenge in the evidence base where long-term outcomes are not fully established.

Evidence for use in Skin and Soft Tissue Infections (SSTIs)

Research exploring the use of Roxithromycin has also been conducted for Skin and Soft Tissue Infections (SSTIs), including conditions characterized by localized inflammatory or irritative states like cellulitis. This evidence mainly comes from comparative short-term Randomized Controlled Trials (RCTs). These studies monitored outcomes linked to inflammatory states, such as measurements of redness and swelling, and also looked at the outcomes related to bacteriological effectiveness, such as whether the targeted bacteria were cleared.

Studies reported patterns observed in the trials where short-term measurements of clinical status were documented across the observed populations. The follow-up durations for these trials were often limited to the time of treatment, meaning data for certain groups remain insufficient regarding infection recurrence or long-term skin health. Furthermore, some research limitations documented in the scientific literature include the difficulty in getting a precise culture of the bacteria causing the infection in all cases, which can affect the certainty of the microbiological outcomes reported.

What is Still Uncertain About Turex Research

The research highlights what is known—and what is still uncertain—about Turex. One persistent limitation across studies is the frequent observation of a potential difference between the successful clinical outcome (patient feeling better) and the continued bacteriological persistence in some individuals. The available research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. The evidence quality varies across studies, and data for certain high-risk groups remain insufficient.

Key Studies & References

  1. Arrow Roxithromycin Tablet Data Sheet (Regulatory Indications)
  2. Roxithromycin and Erythromycin in Chlamydia-negative Non-gonococcal Urethritis

Frequently Asked Questions (FAQ)

Common questions about Turex (FAQ)

Q: What are the approved indications for Turex listed by regulatory bodies?

Official regulatory documents state that Turex is approved to treat infections caused by susceptible bacteria. These typically include respiratory tract infections, skin and soft tissue infections, and certain non-gonococcal genital infections.

Q: How does Turex generally compare to other related medications?

Turex is a semi-synthetic derivative of the older macrolide antibiotic Erythromycin. Official studies indicate that this modification gives Turex improved stability in the stomach’s acid. This structural change is associated with improved bioavailability, meaning the body can absorb and utilize the drug more effectively compared to the original compound.

Q: Are the side effects of Turex usually mild or temporary?

Regulatory documents classify the most frequent side effects, such as nausea and diarrhea, as Common, meaning they are reported in more than 1 out of 100 people. While the labeling describes their frequency, it does not explicitly define how long these common effects are expected to last.

Q: Can Turex affect a person's sleep patterns?

Official reports list effects like headache, dizziness, and vertigo (a feeling of spinning) as possible central nervous system side effects. The official regulatory documents do not list sleep disturbances or insomnia among the reported adverse reactions.

Q: What are the signs or symptoms a patient should look out for after starting Turex?

Regulatory warnings mention that serious symptoms to be aware of include signs of severe allergic reactions or hepatic injury, such as yellowing of the skin or eyes (jaundice). Additionally, persistent, severe diarrhea after starting or stopping the drug can be a sign of a serious intestinal condition known as pseudomembranous colitis.

Q: Are there any known long-term side effects associated with prolonged Turex use?

Official warnings note the possibility of a serious intestinal condition called pseudomembranous colitis, which may occur even weeks after stopping the medication. Prolonged use may also increase the risk of a new infection, known as a superinfection, due to changes in the body's natural flora.

Q: Can Turex be taken at the same time as common over-the-counter pain relievers?

Regulatory documents generally focus on interactions with other prescription medications. However, studies show that co-administering Roxithromycin with acetaminophen (paracetamol) can alter how both drugs are processed by the body. Co-administration is generally addressed by a healthcare professional.

Q: What do official sources say about the combination of alcohol and Turex?

Official guidance mentions that alcohol should be avoided during treatment. This is because alcohol may potentially worsen certain side effects, such as drowsiness, and could interfere with the body's ability to recover from the underlying infection.

Q: How long does it usually take before any effects of Turex might be noticeable?

Official studies indicate that the medicine is rapidly absorbed after being swallowed. Peak plasma levels, meaning the highest concentration of the drug in the bloodstream, are generally reached within two hours of taking the tablet.

Q: What is the typical duration of action for a single dose of Turex?

The drug's plasma half-life—the time it takes for half of the drug to be eliminated from the bloodstream—is approximately 12 hours. This physiological characteristic informs the general approach to treatment frequency.

Q: If a person forgets a dose of Turex, what is the general recommendation provided?

Official information outlines the procedure for missed doses, which includes advice on skipping a dose if the next scheduled dose is approaching. The guidance cautions against taking a double dose to make up for a missed one.

Q: What kind of effects might be expected if a person stops taking Turex suddenly?

Official warnings state that if the medicine is stopped early, it may result in not killing all the targeted bacteria. This incomplete treatment could cause the infection to not clear completely or allow the infection to return.

Q: Is Turex described as needing a certain amount of time to reach its full effect in the body?

Studies of how the drug is processed in the body show that steady state is usually reached within four days of beginning the dosing regimen. Steady state means the level of medicine in the body remains consistent after repeated regular doses.

Q: Has the FDA, EMA, or other regulatory agencies issued any special warnings or alerts concerning Turex?

The most serious warnings in regulatory documents relate to specific contraindications (absolute prohibitions). These include the risk of a severe vascular reaction (ergotism) when taken with certain migraine drugs and the possibility of serious cardiac events (QT interval prolongation) with specific antiarrhythmic medicines.

Q: Where can a patient find the official Prescribing Information or Summary of Product Characteristics for Turex?

Official prescribing information documents, such as the Summary of Product Characteristics (SmPC) or Prescribing Information, are public information. These can generally be accessed through the official websites of national regulatory authorities like the EMA, FDA DailyMed, or TGA.

Q: Is Turex classified as a controlled substance in the US or other regions?

Turex (Roxithromycin) is defined as a prescription-only medicine in most countries. However, it is not listed as a scheduled drug under the US Controlled Substances Act (DEA), meaning it is not classified as a controlled substance.

Q: Why do official documents sometimes refer to Turex by a generic or chemical name?

Official documents use the generic name, Roxithromycin, because it is the active pharmaceutical ingredient (API), which is the chemical substance responsible for the drug's effect. 'Turex' is a specific brand name that a manufacturer uses and may vary across different countries.

Q: What is the general interpretation of Turex's effectiveness based on published clinical evidence?

Studies show that the medicine leads to clinical improvement in people being treated for approved infections. However, official regulatory reviews acknowledge there is uncertainty regarding long-term outcomes and a known difference between a patient feeling better and the actual clearance of the bacteria.

Q: How is Turex generally described in patient information leaflets or Medication Guides?

Patient leaflets typically describe Turex as a macrolide antibiotic that works by stopping the growth of susceptible bacteria. They also contain key information about correct timing, common side effects, and contraindications in accessible language.

Q: Why do official sources sometimes use the term 'adverse reaction' instead of 'side effect'?

Regulatory documents use the term 'adverse reaction' to specifically describe an undesirable effect that is judged to be causally linked to the medicine. This is a technical distinction from the broader term 'side effect,' which includes any unintended effect, regardless of the cause.

Q: What is the potential result if Turex is taken more frequently than what is specified in the instructions?

Taking the medicine more often than specified in the instructions can increase the risk of side effects. This includes the possibility of serious cardiac events related to electrical changes in the heart (QT prolongation).

Q: Is Turex considered to be metabolized by the liver or excreted by the kidneys?

Official information states that the drug is not extensively metabolized (broken down) by the body. The majority of the dose is excreted unchanged into the bile (and eliminated in faeces), with very little eliminated in the urine.

Q: Are there specific laboratory tests that may be required before or during treatment with Turex?

Monitoring is required for certain patient groups during treatment. This includes checking Theophylline levels in some individuals and closely monitoring the INR (International Normalized Ratio) for those taking the anticoagulant Warfarin. Liver function tests may also be monitored in specific groups.

How should Turex be stored and disposed of?

How to Store and Dispose of Turex (Roxithromycin)

Storage and disposal requirements for Turex (Roxithromycin tablets) are set by regulatory bodies to maintain the product's stability and ensure safe environmental handling.

Official Storage Conditions

Requirement Specification
Temperature Store below 25 C (or 30 C in some regions) in a cool, dry place.
Protection Keep protected from direct sunlight, heat, and moisture.
Packaging Keep the product in its original container, which must be tightly closed. Tablets must remain in their blister until use.
Safety The product must be kept out of the reach and sight of children.

Disposal Requirements

Unused or expired Turex must not be thrown away with household garbage or allowed to reach drains or sewage systems. Regulatory instructions require the medicine to be returned to a pharmacist or an official collection point for proper pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Turex found in:

A-Z Index: